CANF Share Price Performance
₪0.01
-0.02 (-62.96%)
Price ₪0.01
Share Price₪0.01
We Think Some Shareholders May Hesitate To Increase Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Compensation
Jun 17
Can-Fite BioPharma Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
CANF Community Narratives
There are no narratives available yet.
Can-Fite BioPharma Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0019
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,571.25%
- Debt/Equity Ratio
- 0%
Can-Fite BioPharma Ltd. Competitors
Snowflake Analysis
About CANF
- Founded
- 1994
- Employees
- 5
- CEO
- WebsiteView website
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Israeli Market Performance
- 7 Days: -0.8%
- 3 Months: 1.1%
- 1 Year: 58.4%
- Year to Date: 30.3%
Over the last 7 days, the market has remained flat, although notably the Utilities sector gained 5.7% in that time. More promisingly, the market is up 58% over the past year. Earnings are forecast to grow by 16% annually. Market details ›